Columbia University Licenses Autoimmune IP to China Group

Columbia University of New York City has licensed worldwide rights covering autoimmune IP to China Institute of Strategy and Management Lanmeng Investment Co., Ltd. The IP posits a model of how the immune system distinguishes between foreign antigens and antigens produced by the individual. The discovery opens new treatment pathways for autoimmune diseases. More details.... Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});